Topotecan for relapsed small cell lung cancer: A systematic review and economic evaluation

Cancer Treatment Reviews

Volumn 37, Issue 3, 2011, Pages 242-249

  Hartwell, Debbie ^a   Jones, Jeremy ^a   Loveman, Emma ^a   Harris, Petra ^a   Clegg, Andrew ^a   Bird, Alex ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cost effectiveness; Small cell lung cancer; Systematic review; Topotecan; Treatment

Indexed keywords

AMRUBICIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; TOPOTECAN; VINCRISTINE;

ANEMIA; BLOOD TOXICITY; CANCER PATIENT; CLINICAL ASSESSMENT; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; ECONOMIC EVALUATION; EMBASE; HUMAN; LIFE EXPECTANCY; LUNG SMALL CELL CANCER; MEDLINE; NEUTROPENIA; OVERALL SURVIVAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TERMINAL CARE; THROMBOCYTOPENIA; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMALL CELL LUNG CARCINOMA; TOPOTECAN;

EID: 79952009253     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.07.005     Document Type: Review

References (35)

1. Rosti G., Bevilacqua G., Bidoli P., Portalone L., Santo A., Genestreti G. Small cell lung cancer. Ann Oncol 2006, 17:ii5-ii10.
2. Hyde L., Yee J., Wilson R., Patno M.E. Cell type and the natural history of lung cancer. JAMA 1965, 193:52-54.
3. Rivera M.P., Detterbeck F.C., Loomis D.P. Epidemiology and classification of lung cancer. Diagnosis and treatment of lung cancer. An evidence-based guide for the practicing clinician 2001, 25-44. WB Saunders Company, Philadelphia. F.C. Detterbeck, M.P. Rivera, M.A. Socinski, J.G. Rosenman (Eds.).
4. Simon G.R., Turrisi A. Management of small cell lung cancer. ACCP evidence-based clinical practice guidelines (2nd ed.). Chest 2007, 132:324S-339S.
5. National Institute for Health and Clinical Excellence (NICE). The diagnosis and treatment of lung cancer. London: NICE; 2005. Clinical Guideline No. 24. Available from: [accessed 03.11.08]. http://www.nice.org.uk/CG024NICEguideline.
6. von Pawel J. The role of topotecan in treating small cell lung cancer: second-line treatment. Lung cancer 2003, 41:S3-S8.
7. Cara S., Tannock I.F. Re-treatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001, 12:23-27.
8. Loveman E., Jones J., Hartwell D., et al. The clinical and cost effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess 2010, 14(19).
9. National Institute for Health and Clinical Excellence (NICE). Topotecan for the treatment of relapsed small-cell lung cancer. London: 2009. Technology Appraisal No. 184. Available from:. http://www.nice.org.uk/TA184.
10. National Institute for Health and Clinical Excellence (NICE). Appraising life-extending, end of life treatments. London: 2009. Available from:<> [accessed 21.08.09]. http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf.
11. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1980, 47:207-214.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
13. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. York: York Publishing Services Ltd.; 2001. CRD Report No. 4 (2nd ed.).
14. Drummond M.F., Sculpher M.J., O'Brien B.J., Stoddart G.L., Torrance G.W. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford.
15. Philips Z., Ginnelly L., Sculpher M., et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004, 8:1-158.
16. Cochrane Collaboration. Assessing risk of bias in included studies. In: Higgins J, Altman D, editors. Cochrane Handbook for Systematic Reviews of Interventions 2007. Available from: http://www.cochrane.org/resources/handbook/Handbook5_Bias_V10.pdf.
17. Eckardt J.R., von Pawel J., Pujol J.L., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25:2086-2092.
18. O'Brien M.E., Ciuleanu T.E., Tsekov H., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441-5447.
19. von Pawel J., Gatzemeier U., Pujol J.L., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001, 19:1743-1749.
20. von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
21. Eckardt T., von Pawel J., Hainsworth J.D., et al. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study [abstract]. Proc Am Soc Clin Oncol 2003, 22:619.
22. Schiller J., von Pawel J., Shepherd F., et al. Topotecan (t) versus (vs) cyclophosphamide (c), doxorubicin (a) and vincristine (v) for the treatment (tx) of patients (pts) with recurrent small cell lung cancer (sclc): a phase III study [abstract]. Proc Am Soc Clin Oncol. 1998, 17:1755.
23. Sugawara S., Inoue A., Yamazaki K., et al. Randomized, phase II trial comparing amrubicin with topotecan in patients (pts) with previously treated small cell lung cancer (SCLC). J Clin Oncol 2008, 26:8042.
24. Inoue A., Sugawara S., Yamazaki K., et al. Randomized Phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008, 26:5401-5406.
25. Chen L., Antras L., Duh M., Pickard S., Cella D., Neary M., et al. Is treatment with oral topotecan plus best supportive care associated with better health status compared to best supportive care alone in small cell lung cancer? [abstract]. J Thoracic Oncol 2007, 2:S391-S392.
26. O'Brien M.E., Duh M.S., Chen L., Antras L., Neary M., Gralla R.J. An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomized Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial [abstract]. J Thoracic Oncol 2007, 2:S827.
27. Hycamtin: summary of product characteristics. 2009 [accessed 02.02.09]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Hycamtin/H-123-PI-en.pdf.
28. Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2008.
29. GlaxoSmithKline UK. Multiple technology appraisal of topotecan for the treatment of small cell lung cancer; 2008.
30. Main C., Bojke L., Griffin S., et al. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2006, 10(9).
31. Oliver E., Killen J., Kiebert G., et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001, 56:785-790.
32. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. Available from:<> [accessed 26.01.09]. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
33. Richards M. Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards. Available from: [accessed 14.08.09]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089927.
34. National Institute for Health and Clinical Excellence (NICE). Update report on the application of the 'end-of-life' supplementary advice in health technology appraisals. Available from: [accessed 14.08.09]. http://www.nice.org.uk/media/835/8E/item7endoflifetreatments.pdf.
35. Raftery J. NICE and the challenges of cancer drugs. BMJ 2009, 338:271-272.